Eli Lilly partners with Hims & Hers to expand self-pay access to Zepbound and Foundayo, with monthly prices starting at $149 and $299.
Written By: Rishabh Sonawane, BPharm
Reviewed By: Pharmacally Editorial Team
Eli Lilly has entered an agreement with Hims & Hers Health to expand access to its FDA-approved obesity medicines, Zepbound (tirzepatide) and Foundayo (orforglipron), through the digital health platform. The arrangement offers eligible patients access to Lilly’s self-pay pricing, starting at $149 per month for Foundayo and $299 per month for Zepbound, without leaving the Hims & Hers platform.
Agreement Integrates Lilly’s Obesity Medicines into Digital Healthcare
Under the agreement, patients can consult licensed healthcare providers through Hims & Hers, obtain a prescription when clinically appropriate, and receive their medication through home delivery. The arrangement integrates medical consultations, prescription access, medication fulfilment and ongoing follow-up care within a single digital platform.
The partnership combines Lilly’s growing obesity treatment portfolio with Hims & Hers’ established telehealth infrastructure. It also provides another distribution channel for Lilly as pharmaceutical companies increasingly explore direct-to-patient models to improve access to prescription medicines.
The starting monthly self-pay prices are $149 for Foundayo and $299 for Zepbound. These prices match the self-pay prices Lilly makes available to other patients, according to the companies. The announcement does not specify additional eligibility requirements, prescription restrictions or whether the prices apply uniformly across all treatment strengths.
Two Different GLP-1 Approaches Address Obesity Treatment
The agreement covers two medicines with distinct pharmacological profiles.
Zepbound contains tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It acts on both incretin pathways to regulate appetite, food intake and metabolic activity. The injectable medicine is approved in the United States for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, alongside reduced-calorie eating and increased physical activity.
Foundayo contains orforglipron, an oral, non-peptide GLP-1 receptor agonist. Unlike injectable peptide-based GLP-1 medicines, its small-molecule structure allows once-daily oral administration. Its availability adds an oral treatment option to Lilly’s obesity portfolio.
Offering both medicines through the same telehealth platform gives eligible patients access to different administration routes and pharmacological approaches. However, treatment selection remains dependent on individual clinical assessment rather than platform availability alone.
Independent Prescribing Remains a Key Condition
Both companies have committed to maintaining independent clinical decision-making under the agreement. Healthcare providers on the Hims & Hers platform will retain responsibility for determining the appropriate treatment for each patient.
The companies also clarified that Hims & Hers has never offered compounded copies of Lilly’s GLP-1 medicines and has committed not to offer them in the future.
This provision is particularly relevant to the US obesity drug market, where the availability of compounded GLP-1 products has raised regulatory and pharmaceutical industry concerns around product quality, oversight and the distribution of unapproved copies of branded medicines.
Digital Distribution Strengthens Lilly’s Direct-to-Patient Strategy
Hims & Hers will support patients beyond the initial consultation through its existing weight-loss membership programme. Services include round-the-clock access to a care team, nutrition guidance, regular clinical check-ins and participation in its weight-loss community.
Lilly USA President Ilya Yuffa said the agreement would help patients access FDA-approved treatments through a platform they already use for healthcare services. Hims & Hers CEO Andrew Dudum highlighted the partnership’s potential to connect pharmaceutical innovation with digital healthcare delivery.
The agreement represents a commercial distribution development rather than a new clinical or regulatory milestone for either medicine. It does not introduce new indications, modify existing prescribing requirements or establish additional efficacy or safety evidence.
For Lilly, the collaboration expands access to its obesity portfolio through a major digital healthcare channel while maintaining branded-product distribution. For Hims & Hers, it adds direct access to two FDA-approved obesity medicines within its existing weight-management services.
The longer-term significance will depend on patient uptake, treatment continuity, affordability and the ability of the platform to maintain appropriate clinical oversight as demand for prescription obesity medicines continues to grow.
Reference
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines, Lilly, 06 November 2026
About the Writer
Rishabha Sonawane, B.Pharm (LinkedIn) is healthcare writer with a strong interest in medical writing, regulatory affairs, clinical research, and AI-driven drug discovery. He has completed specialized training from the NIH and ICMR in clinical pharmacology, clinical research, and scientific writing. Passionate about evidence-based healthcare communication, he focuses on translating complex scientific research into clear, accurate, and engaging medical content.